How Should Product Classification Be Determined for Medical Device Registration in Thailand?

Answer: Medical device registration in Thailand generally requires first confirming the product classification and applicable pathway, then preparing technical documents, labels and instructions for use, quality management system (QMS) evidence, authorization documents, and local representative information. Existing NMPA materials can serve as a foundation, but they usually need to be adapted to Thai FDA (TFDA) requirements for language, format, labeling, and evidence-chain consistency.

Published: 2026-07-10 11:35 | Updated: 2026-07-10 11:35

This FAQ addresses priority issues companies need to judge in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Key Summary

• Medical device registration in Thailand usually requires confirming product classification and the applicable pathway before preparing technical files, labels and instructions for use, QMS evidence, authorization documents, and local representative materials.
• Existing NMPA materials can serve as a basis, but they generally need adaptation to Thai FDA requirements for language, format, labeling, and evidence chain.
• For Chinese medical device companies, a more prudent approach is to first complete a product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused.
• Thai registration often affects technical files, authorized representative arrangements, importer cooperation, label language, QMS evidence, and subsequent change maintenance. If the project is advanced only by asking which documents to submit, deficiencies or rework may arise in model coverage, evidence-chain consistency, label claims, and certificate control.
• AIMEILI recommends planning this issue within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets instead of recreating documents temporarily for each country.
• Companies should also make project-based judgments based on the latest requirements of the target country regulator, the existing technical file basis, product risk class, and launch plan, rather than preparing mechanically according to a document checklist.
• Compiled from AIMEILI registration practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Issues

Companies searching for how to determine product classification for medical device registration in Thailand usually want to solve practical questions rather than obtain a conceptual explanation: whether existing materials can support a Thai submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first create reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence, and labels and instructions for use, and then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it is active, and whether it contains software or has IVD attributes, and then determine the risk class and submission pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary materials will deviate from the correct direction.

For a Thai project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in commercial contracts, market control rights may easily be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to document quality is not quantity but consistency. Instructions for use claims, model coverage of test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Translating and submitting domestic NMPA materials directly without rearranging the evidence according to the Thai pathway.
• Having too many models or specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent only based on sales cooperation, without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance responsibilities.
• Having inconsistencies among labels, instructions for use, promotional materials, and registration dossier claims, leading to deficiencies or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

Before launching a project, companies are advised to use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA, or other market registration materials can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table and identify content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not view Thai registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to each country's requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing materials country by country on an ad hoc basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency response, agent communication, and post-market maintenance.

Frequently Asked Follow-Up Questions

Can domestic Chinese materials be used directly for Thai registration?

Domestic Chinese materials can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, QMS documents are not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the scope covered by the ISO 13485 certificate does not match the declared product, or if the manufacturing address, model and specification, instructions for use version, and test reports are inconsistent, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and QMS certificate item by item. This action may appear basic, but it can significantly reduce the probability of deficiencies, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product series.

Localization Conversion and Agent Responsibilities

Thai registration projects often involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market materials, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest substantial effort in obtaining the certificate but neglect post-market maintenance. Later, once there is a manufacturing address change, model expansion, instructions for use update, or agent replacement, the certificate and market sales can easily become disconnected.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of doing so is not only to improve registration efficiency in a single country, but more importantly to help companies build a replicable overseas compliance capability and reduce the cost of starting document preparation from scratch each time they enter a new market.

Continue Reading

• Previous: How Should Registration Materials Be Prepared for Medical Device Registration in Thailand?
• Next: How Should Technical Files Be Organized for Medical Device Registration in Thailand?

Recommended Reading

• How Should Registration Materials Be Prepared for Medical Device Registration in Malaysia?
• How Should Product Classification Be Determined for Medical Device Registration in Malaysia?
• How Should Technical Files Be Organized for Medical Device Registration in Malaysia?
• How Should Labels and Instructions for Use Be Localized for Medical Device Registration in Malaysia?
• How Should Clinical Evaluation Materials Be Prepared for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Return to FAQ Center

News and Information | Contact AIMEILI

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as supporting judgment.

Applicability boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulator, test conclusions, or legal advice.